pf-04236921

mAbexperimental

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • pf-04236921
  • pf-04236921

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03038971Phase 1Mar 30, 2017Greer Laboratories, ORA, Inc.
NCT02134262Phase 1/Phase 2 (Phase 2)May 1, 2014Jichi Medical University, Takara Bio Inc.
NCT01405196Phase 2Dec 1, 2011Pfizer
NCT01345318Phase 2Jun 1, 2011Pfizer
NCT01287897Phase 2Feb 1, 2011Pfizer
NCT01166555Phase 1May 1, 2010Pfizer
NCT00838565Phase 1May 1, 2009Pfizer
NCT00626626Phase 1/Phase 2 (Phase 2)May 1, 2007Pennsylvania State University
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit5522009
Greer LaboratoriesFor profit1112017
Jichi Medical UniversityAcademic/Hospital1112014
ORA, Inc.For profit1012017
Pennsylvania State UniversityAcademic/Hospital1112007
Takara Bio Inc.For profit1012014
6 organizations
Page 1 / 1